Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23926345 | 0.96 | PREP (0.41) | APPMEN1KMT2APREP | |
| SCHEMBL30118928 | 0.89 | KLK7 (0.44) | APPMEN1KMT2AFKBP1APREP | |
| SCHEMBL23964599 | 0.89 | KLK7 (0.44) | APPMEN1KMT2AFKBP1APREP | |
| SCHEMBL23964440 | 0.85 | KLK7 (0.47) | MEN1KMT2APREPALDH1A1 | |
| SCHEMBL30118918 | 0.85 | KLK7 (0.47) | MEN1KMT2APREPALDH1A1 | |
| SCHEMBL30369775 | 0.84 | PREP (0.37) | APPMEN1KMT2ASGMS2PREP | |
| SCHEMBL23926358 | 0.84 | PREP (0.37) | APPMEN1KMT2ASGMS2PREP | |
| SCHEMBL30369839 | 0.82 | KLK7 (0.43) | APPMEN1KMT2AFKBP1APREP | |
| SCHEMBL23926386 | 0.81 | GHSR (0.37) | PREP | |
| SCHEMBL30369527 | 0.81 | GHSR (0.37) | PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667256-A | Compounds for treating diseases and methods of treating diseases | 艾特里提治疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | APP 67/4885MEN1 1161/4885KMT2A 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.